Bill has served as our Chief Business Development Officer since September 2010, as the Executive Chairman of our board of directors since March 2009, and as a director since January 2006. From August 1997 to September 2010, Bill served in various roles at Diversa Corporation (now known as Verenium Corporation), a biotechnology company focused on the development of biofuels, including Vice President Sales and Marketing from August 1997 to November 1999, Senior Vice President, Business Development from November 1999 to July 2002 and Executive Vice President, Business Development from July 2002 to August 2010. Prior to joining Diversa, Bill served as the Vice President of Global Sales and Marketing at International Specialty Products, Inc., a specialty chemicals company and held a variety of executive positions, both in the United States and internationally, at Betz Laboratories, Inc., a specialty chemicals company. Bill holds a B.S. in Chemistry from Widener University.

Christophe co-founded Genomatica and has served as our Chief Executive Officer since May 2009. Christophe holds a Ph.D. in bioengineering from the University of California, San Diego where he was a Powell Foundation and Whitaker Foundation Fellow. He received a B.S. in biomedical engineering from Duke University where he was a Howard Hughes Undergraduate Research Fellow. Christophe’s awards include the Top 100 Young Innovators from MIT’s Technology Review, R&D100 for the SimPheny part of the company’s technology platform, and the Distinguished Young Alumnus from Duke University’s Edmund T. Pratt, Jr. School of Engineering.

Warren has served on our board of directors since July 2007. From June 1970 to July 2002, Warren served as Global Director of Technology Licensing at Dow, and before that held a series of senior leadership roles in operations and commercial management, including president and general manager, of a Dow subsidiary. Warren currently provides consulting services to the chemical industry. He holds an M.B.A. with a major in finance from the Central Michigan University and a B.S. in chemical engineering from Kansas State University.

Josh has served on our board of directors since July 2007. Mr. Green has been a general partner at Mohr Davidow Ventures since December 2006 with a focus on the clean technologies industry. From August 1995 until October 2003, Josh practiced law at Venture Law Group, and prior to that he practiced law at Brobeck, Phleger & Harrison LLP from September 1980 to August 1995. Josh also serves as a director on several privately held companies in the cleantech and life science spaces. He holds a J.D. from the University of California, Los Angeles School of Law and a B.A. in political science from University of California, Los Angeles.

Thomas has served on our board of directors since March 2011. He has been a partner at VantagePoint Capital Partners since November 2004, where he currently serves in its CleanTech Practice Group. Previously, he was an analyst with CDP Capital Technology Ventures and before that served as Project Manager for Genopole, a business incubator company specializing in biotechnology companies. Thomas also serves as a director on several privately held companies in the cleantech space. He holds a Ph.D. in Biochemistry and Molecular Biology from University College London and a B.S. in Biochemistry from Université Paris XI, Orsay.

Patrick has served on our board of directors since January 2010. Since October 2007, Patrick has been a principal at TPG Biotech with a focus on the industrial biotechnology sector. From May 2006 to October 2007, Patrick was the Chief Financial Officer of Ceres, Inc., a plant biotechnology company focusing on second generation biofuels production. From December 1999 to December 2005, Patrick was Vice President of Business Development at Diversa Corporation. After spending ten years at Dow in various technical and business positions, from November 1988 to December 1997, Patrick served as Vice President of Finance and Strategic Planning at Intarsia Corporation, a joint venture between Dow and Flextronics International created to commercialize novel flat panel thin film technology for integrated electronic devices. Patrick also serves as a director on several privately held companies in the cleantech and life science spaces. He holds an M.S. and Ph.D. in Chemical Engineering from Carnegie Mellon University and a B.S. from West Virginia University.

Leighton has served on our board of directors since July 2007. From 2001 until 2007, He served as a Managing Member in four funds at Alloy Ventures, where he continues as a Venture Partner. Prior to that, Leighton founded Aviron, a biopharmaceutical company focused on vaccines for infectious disease, where he served as Chairman of the Board and Chief Executive Officer until December 1999 and as a director until its acquisition in January 2002 by MedImmune, Inc. In 1989, he co-founded Affymax NV, a biopharmaceutical company. Leighton currently serves as a director of Alexza Pharmaceuticals, Inc., a pharmaceutical company, and various private companies. He has also previously served as director for a number of other biotechnology companies and on the executive committee of the Biotechnology Industry Association. Leighton holds an M.D. from the University of Texas Health Science Center at San Antonio and completed his training in internal medicine at Duke University and holds a B.S. from Rice University in Psychology and Biology.

Michael has served on our board of directors since May 2004 and served as our interim Chief Executive Officer from August 2007 until February 2008. From January 1991 to June 1998, Michael was President and Chief Executive Officer of Molecular Simulations, Inc. (now known as Accelrys, Inc.), a computer-aided drug discovery software company, until its merger with Pharmacopeia, a biotechnology platform company in June 1998 and served as a director and vice president of Pharmacopeia from June 1998 to January 1999. He holds an M.S. in Biology from the California Institute of Technology and a B.S. in Chemistry and Biology from Fort Lewis College.

Geoff joined TPG in 2004 and currently serves as Partner and Managing Director.  Previously, Geoff served on the Board of Directors and was President of Research & Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff and Vice President of Genomics at Millennium Pharmaceuticals.

Geoff has also been an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI).  He graduated from Wesleyan University (1980) with a BA in Biology and was elected to Phi Beta Kappa. He holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr.Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.

Steve is a Managing Director of Draper Fisher Jurvetson.  Steve was the founding VC investor in Hotmail, Interwoven, and Kana and led the firm’s investments in Tradex and Cyras, along with companies in synthetic biology and molecular electronics.

At Stanford, he finished his BSEE in 2.5 years and graduated #1 in his class. He also received an MSEE and MBA from Stanford, and serves as Co-Chair of the NanoBusiness Alliance and President of the Western Association of Venture Capitalists.

Bernhard is the Galetti Professor of Bioengineering and Adjunct Professor Medicine at the University of California, San Diego, where he has been since 1995.  Prior to joining the faculty at UCSD, Professor Palsson held a faculty position at the University of Michigan from 1984 to 1995.

He co-founded a biotechnology company, Aastrom Biosciences (NASDAQ: ASTM) in 1988, where he served as the Vice President of Developmental Research for two years. He is also co-founder of Oncosis (later renamed Cyntellect) and Genomatica. He  earned a Ph.D. from the University of Wisconsin in 1984.

Robert was Vice President of Central Research at Dow Chemical before founding Pangborn Associates, LLC in 1998. He spent over two decades at Dow, including serving on the Members’ Committee of Cargill Dow Polymers, currently known as NatureWorks. As Pangborn Associates, Robert has consulted with Diversa (now Verenium), Metabolix, Materia, Novomer and CSP Technologies.

Robert holds a PhD. in physics from Dartmouth, attended Harvard Business School Program for Management Development, and was an officer in the U. S. Marine Corps.

Carl is Senior Vice President, Organic Growth at Waste Management. Carl joined Waste Management in 2001 as Director of the In-Plant Services Group, now called Upstream. In early 2005, he became Vice President of Upstream and a year later accepted the position of Vice President of Organic Growth. Before joining Waste Management, Carl was President and CEO of The GNI Group for 15 years. He received a bachelor’s degree in business and a master’s degree in business administration from Texas Christian University.

Boris was appointed to the position of Deputy Director General, RU-COM, in October 2009.  From 2008 he was Director for Investments and Assessment.  From 2003 till 2007 Boris was Director for Strategic Development and Technologies at 36.6 Pharmacy Chain. Previously, he held various positions at McKinsey and JSB Rosbank. In 2001 he graduated from the International Institute of Economic Relations, the Financial Academy under the Government of the Russian Federation, in 2004 he defended a thesis with a major in “World Economy” and obtained a degree of Cand. Sc. (Economics). In 2009 he graduated from Warwik University, UK, and obtained his MBA.